| evidence domain | source/model | main finding | quantitative/example data | strength/limitation |
|---|---|---|---|---|
| Foundational human disease description | Human families with biallelic DNAJC3 loss | DNAJC3 deficiency causes a syndromic disorder combining juvenile/early-onset diabetes with central and peripheral neurodegeneration, often including ataxia, hearing loss, cognitive impairment, short stature, hypothyroidism, retinal findings, and pancreatic abnormalities (pqac-00000015, pqac-00000019, pqac-00000000, pqac-00000001) | Reported features across cases include ataxia, peripheral neuropathy, sensorineural hearing loss, retinal dystrophy, short stature, hypothyroidism, and pancreatic atrophy/hypoplasia; diabetes is generally non-autoimmune (pqac-00000015, pqac-00000000, pqac-00000001) | Strong syndrome-level consistency across independent families; limitation: very small number of published patients and incomplete ascertainment (pqac-00000019, pqac-00000000) |
| Inheritance and causal variants | Human pedigrees/case series | Inheritance is autosomal recessive with homozygous or compound-heterozygous loss-of-function variants in DNAJC3 (pqac-00000000, pqac-00000002, pqac-00000019) | Examples: p.Arg194*; large homozygous deletion spanning exons 6-12; p.Arg393*; p.Arg346*/p.Met1Val; splice-site c.393+2T>G and c.393+2T>C; c.1367_1370delAGAA (p.Lys456SerfsTer85) (pqac-00000019, pqac-00000000, pqac-00000002, pqac-00000004) | Multiple recurrent LoF alleles support causality; limitation: no robust penetrance or population-frequency summary available from the retrieved evidence (pqac-00000019, pqac-00000004) |
| 2024 metabolic expansion study | Human index case plus young knockout mice | Hyperinsulinemic hypoglycemia can be a primary manifestation of DNAJC3 deficiency and may precede later diabetes, supporting a biphasic endocrine phenotype (pqac-00000015, pqac-00000013, pqac-00000014) | Human case: recurrent hypoglycemia from infancy; diazoxide responsive; persisted into adolescence. Mouse: 4-week-old KO mice had reduced total in vivo insulin secretion capacity but increased high-glucose-stimulated insulin release at islet level (pqac-00000013, pqac-00000014) | Valuable because it integrates patient and mechanistic mouse data; limitation: largely driven by one newly described human case and preclinical inference (pqac-00000013, pqac-00000014) |
| Human endocrine natural history | Human cases/siblings | Insulin dysregulation appears age-related, with early hyperinsulinism/hypoglycemia in some patients and later hyperglycemia/diabetes in adolescence or adulthood (pqac-00000003, pqac-00000005, pqac-00000019) | Ocansey report explicitly describes a spectrum “evolving from hyperinsulinaemic hypoglycaemia to diabetes mellitus”; one prior case had infancy hypoglycemia before diabetes at age 12 years (pqac-00000003, pqac-00000019) | Suggestive and clinically important; limitation: natural history remains poorly defined because longitudinal data are sparse (pqac-00000005, pqac-00000019) |
| Human neurologic phenotype | Human case reports/series | Neurologic involvement affects both central and peripheral nervous systems, including cerebellar/peripheral ataxia, developmental delay or cognitive impairment, and demyelinating/sensorimotor neuropathy (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000000) | Example findings: peroneal motor nerve conduction velocity 31 m/s indicating demyelinating neuropathy; generalized myelin maturation delay; white-matter lesions; progressive gait ataxia (pqac-00000003, pqac-00000004, pqac-00000013) | Reproducible multisystem phenotype across reports; limitation: severity is variable, and some patients show only subtle neurologic abnormalities early in life (pqac-00000013, pqac-00000001) |
| Imaging/anatomical evidence | Human MRI/imaging | Pancreatic atrophy/hypoplasia and neuroimaging abnormalities are emerging components of the phenotype (pqac-00000000, pqac-00000001, pqac-00000016) | Small/atrophic pancreas on MRI in two siblings; other reports note small anterior pituitary and white-matter lesions (pqac-00000000, pqac-00000001, pqac-00000004, pqac-00000013) | Supports multisystem structural involvement; limitation: imaging has not been performed systematically across cases (pqac-00000016) |
| Molecular mechanism: normal DNAJC3 function | Human/cell biology synthesis in disease-focused papers | DNAJC3 is an ER-resident BiP co-chaperone that helps refold misfolded proteins and dampens PERK-mediated UPR signaling; deficiency disrupts ER homeostasis and promotes apoptosis (pqac-00000015, pqac-00000017) | Functions described include BiP-assisted refolding in the ER lumen and indirect inhibition of PERK/eIF2α signaling during sustained stress (pqac-00000015, pqac-00000017) | Mechanistically coherent across disease papers; limitation: mostly inferred from cell and animal systems rather than direct human tissue experiments (pqac-00000015, pqac-00000017) |
| Patient-cell proteomics and organelle pathology | Patient-derived fibroblasts/proteomics | Loss of DNAJC3 is associated with perturbed lipid/cholesterol metabolism, ER-Golgi dysfunction, amyloid precursor protein defects, and mitochondrial morphology/OXPHOS abnormalities (pqac-00000011, pqac-00000017) | Reported observations include intracellular lipid accumulation, increased sensitivity to cholesterol stress, UPR activation, ER-Golgi alterations, β-amyloid accumulation, and impaired mitochondrial oxidative phosphorylation (pqac-00000011, pqac-00000017) | Strong mechanistic depth from unbiased proteomics plus functional assays; limitation: fibroblasts may not fully model pancreatic beta cells or neurons (pqac-00000011) |
| Beta-cell injury mechanism | Human islets/cell lines/mouse | DNAJC3 deficiency promotes beta-cell dysfunction and apoptosis, providing a mechanistic basis for diabetes (pqac-00000010, pqac-00000008, pqac-00000011) | Evidence cited includes apoptosis in INS-1E cells, primary rat beta cells, and human islets; KO mice develop hypoinsulinemia and gradual hyperglycemia with age (pqac-00000010, pqac-00000008) | Cross-species convergence supports pathogenic mechanism; limitation: limited direct histopathology from affected human pancreas (pqac-00000008, pqac-00000016) |
| Proposed hyperinsulinism mechanism | Human+mouse mechanistic proposal | Early hyperinsulinism may result from excessive ER-to-cytosol calcium leak via Sec61 when DNAJC3/BiP gating is impaired (pqac-00000014, pqac-00000010) | Human concept linked to diazoxide-responsive HH; mouse islets showed significantly higher insulin release during high-glucose stimulation despite lower insulin content (pqac-00000014, pqac-00000010) | Novel and disease-specific mechanistic hypothesis; limitation: calcium imaging confirmation in DNAJC3-deficient human islets is still lacking (pqac-00000014) |
| Real-world management | Human case reports | Management is supportive and phenotype-directed: diazoxide for HH, insulin or metformin/lifestyle for diabetes, levothyroxine for hypothyroidism, and multidisciplinary neurologic/endocrine follow-up (pqac-00000004, pqac-00000007, pqac-00000000, pqac-00000001) | Diazoxide doses reported from 7.5-10 mg/kg/day initially, tapered to 2.2 mg/kg/day by age 14 in one patient; one diabetic sibling initially used metformin/lifestyle then later insulin (pqac-00000013, pqac-00000007, pqac-00000000) | Directly relevant to current care; limitation: no disease-specific trials or standardized treatment algorithms were identified (pqac-00000007, pqac-00000000) |
| Growth hormone experience | Human case reports/literature review | rhGH has shown limited growth benefit and may raise concern for worsening hyperglycemia in patients with limited beta-cell reserve (pqac-00000016, pqac-00000001) | Off-label GH and recombinant IGF-1 showed no meaningful growth response in the 2024 case; 2021 review suggested hyperglycemia risk may outweigh benefit (pqac-00000013, pqac-00000016) | Helpful caution for endocrine management; limitation: based on small uncontrolled observations (pqac-00000016, pqac-00000013) |
| Evidence gaps | Across literature | Major gaps remain in epidemiology, formal diagnostic criteria, prognostic biomarkers, genotype-phenotype correlations, omics biomarkers in target tissues, and interventional trials (pqac-00000019, pqac-00000016, pqac-00000014) | No prevalence/incidence estimates, no disease-specific clinical trials retrieved, and only limited longitudinal natural-history data were available (pqac-00000019, pqac-00000014) | Important for knowledge-base completeness; limitation: absence of data should not be interpreted as absence of effect or absence of clinical relevance (pqac-00000019, pqac-00000014) |


*Table: This table condenses the strongest currently retrieved evidence for DNAJC3-related juvenile-onset diabetes with multisystemic neurodegeneration, spanning human case reports, the 2024 human-plus-mouse study, fibroblast proteomics, management observations, and key knowledge gaps.*